BioCentury

7:00 AM GMT, May 12, 2016
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Distillery Therapeutics

Therapeutics: Peripheral benzodiazepine receptor (TSPO; PBR); Mdm2 p53 binding protein homolog (MDM2; HDM2)

Cancer

INDICATION: Brain cancer

In vitro studies identified an inhibitor of MDM2/p53 binding and TSPO that could

Read the full 150 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.